E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion

S. M. Anderson, L. Wideman, J. T. Patrie, A. Weltman, C. Y. Bowers, Johannes D Veldhuis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Female gender confers resistance to GH autonegative feedback in the adult rat, thereby suggesting gonadal or estrogenic modulation of autoregulation of the somatotropic axis. Here we test the clinical hypothesis that short-term E2 replacement in ovariprival women reduces GH's repression of spontaneous, GHRH-, and GH-releasing peptide (GHRP)-stimulated GH secretion. To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17β-E2 orally twice daily for 6-23 d]. The GH autofeedback paradigm consisted of a 6-min pulsed iv infusion of recombinant human GH (10 μg/kg square-wave injection) or saline (control) followed by iv bolus GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or saline 2 h later. Blood was sampled every 10 min and serum GH concentrations were measured by chemiluminescence. Poststimulus GH release was quantitated by multiparameter deconvolution analysis using published biexponential kinetics and by the incremental peak serum GH concentration response (maximal poststimulus value minus prepeak nadir). Outcomes were analyzed on the logarithmic scale by mixed-effects ANOVA at a multiplecomparison type I error rate of 0.05. E2 supplementation increased the (mean ± SEM) serum E2 concentration from 43 ± 1.8 (control) to 121 ± 4 pg/ml (E2) (158 ± 6.6 to 440 ± 15 pmol/ liter; P < 0.001), lowered the 0800 h (preinfusion) serum IGF-I concentration from 127 ± 7.7 to 73 ± 3.6 μg/liter (P < 0.01), and amplified spontaneous pulsatile GH production from 7.5 ± 1.1 to 13 ± 2.3 μg/liter per 6 h (P = 0.020). In the absence of exogenously imposed GH autofeedback, E2 replacement enhanced the stimulatory effect of GHRP-2 on incremental peak GH release by 1.58-fold [95% confidence interval, 1.2- to 2.1fold] (P = 0.0034) but did not alter the action of GHRH (0.83fold [0.62- to 1.1-fold]). In the E2-deficient state, bolus GH infusion significantly inhibited subsequent spontaneous, GHRH-, and GHRP-induced incremental peak GH responses by, respectively, 33% (1-55%; P = 0.044 vs. saline), 79% (68-86%; P < 0.0001), and 54% (32-69%; P = 0.0002). E2 repletion failed to influence GH autofeedback on either spontaneous or GHRH-stimulated incremental peak GH output. In contrast, E2 replenishment augmented the GHRP-2-stimulated incremental peak GH response in the face of GH autoinhibition by 1.7-fold (1.2- to 2.5-fold; P = 0.009). Mechanistically, the latter effect of E2 mirrored its enhancement of GH-repressed/GHRP2-stimulated GH secretory pulse mass, which rose by 1.5-fold (0.95- to 2.5-fold over placebo; P = 0.078). In summary, the present clinical investigation documents the ability of short-term oral E2 supplementation in postmenopausal women to selectively rescue GHRP-2 (but not spontaneous or GHRH)stimulated GH secretion from autonegative feedback. The secretagogue specificity of E's relief of GH autoinhibition suggests that this sex steroid may enhance activity of the hypothalamopituitary GHRP-receptor/effector pathway.

Original languageEnglish (US)
Pages (from-to)5904-5911
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number12
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Feedback
Peptides
Serum
Placebos
Chemiluminescence
Deconvolution
Analysis of variance (ANOVA)
Luminescence
Insulin-Like Growth Factor I
Rats
Analysis of Variance
Healthy Volunteers
Homeostasis
Blood
Steroids
Modulation
Confidence Intervals
Scanning electron microscopy
Injections
Kinetics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion. / Anderson, S. M.; Wideman, L.; Patrie, J. T.; Weltman, A.; Bowers, C. Y.; Veldhuis, Johannes D.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 12, 2001, p. 5904-5911.

Research output: Contribution to journalArticle

Anderson, S. M. ; Wideman, L. ; Patrie, J. T. ; Weltman, A. ; Bowers, C. Y. ; Veldhuis, Johannes D. / E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion. In: Journal of Clinical Endocrinology and Metabolism. 2001 ; Vol. 86, No. 12. pp. 5904-5911.
@article{1d24880110264684a7da2201b4ae86ab,
title = "E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion",
abstract = "Female gender confers resistance to GH autonegative feedback in the adult rat, thereby suggesting gonadal or estrogenic modulation of autoregulation of the somatotropic axis. Here we test the clinical hypothesis that short-term E2 replacement in ovariprival women reduces GH's repression of spontaneous, GHRH-, and GH-releasing peptide (GHRP)-stimulated GH secretion. To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17β-E2 orally twice daily for 6-23 d]. The GH autofeedback paradigm consisted of a 6-min pulsed iv infusion of recombinant human GH (10 μg/kg square-wave injection) or saline (control) followed by iv bolus GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or saline 2 h later. Blood was sampled every 10 min and serum GH concentrations were measured by chemiluminescence. Poststimulus GH release was quantitated by multiparameter deconvolution analysis using published biexponential kinetics and by the incremental peak serum GH concentration response (maximal poststimulus value minus prepeak nadir). Outcomes were analyzed on the logarithmic scale by mixed-effects ANOVA at a multiplecomparison type I error rate of 0.05. E2 supplementation increased the (mean ± SEM) serum E2 concentration from 43 ± 1.8 (control) to 121 ± 4 pg/ml (E2) (158 ± 6.6 to 440 ± 15 pmol/ liter; P < 0.001), lowered the 0800 h (preinfusion) serum IGF-I concentration from 127 ± 7.7 to 73 ± 3.6 μg/liter (P < 0.01), and amplified spontaneous pulsatile GH production from 7.5 ± 1.1 to 13 ± 2.3 μg/liter per 6 h (P = 0.020). In the absence of exogenously imposed GH autofeedback, E2 replacement enhanced the stimulatory effect of GHRP-2 on incremental peak GH release by 1.58-fold [95{\%} confidence interval, 1.2- to 2.1fold] (P = 0.0034) but did not alter the action of GHRH (0.83fold [0.62- to 1.1-fold]). In the E2-deficient state, bolus GH infusion significantly inhibited subsequent spontaneous, GHRH-, and GHRP-induced incremental peak GH responses by, respectively, 33{\%} (1-55{\%}; P = 0.044 vs. saline), 79{\%} (68-86{\%}; P < 0.0001), and 54{\%} (32-69{\%}; P = 0.0002). E2 repletion failed to influence GH autofeedback on either spontaneous or GHRH-stimulated incremental peak GH output. In contrast, E2 replenishment augmented the GHRP-2-stimulated incremental peak GH response in the face of GH autoinhibition by 1.7-fold (1.2- to 2.5-fold; P = 0.009). Mechanistically, the latter effect of E2 mirrored its enhancement of GH-repressed/GHRP2-stimulated GH secretory pulse mass, which rose by 1.5-fold (0.95- to 2.5-fold over placebo; P = 0.078). In summary, the present clinical investigation documents the ability of short-term oral E2 supplementation in postmenopausal women to selectively rescue GHRP-2 (but not spontaneous or GHRH)stimulated GH secretion from autonegative feedback. The secretagogue specificity of E's relief of GH autoinhibition suggests that this sex steroid may enhance activity of the hypothalamopituitary GHRP-receptor/effector pathway.",
author = "Anderson, {S. M.} and L. Wideman and Patrie, {J. T.} and A. Weltman and Bowers, {C. Y.} and Veldhuis, {Johannes D}",
year = "2001",
doi = "10.1210/jc.86.12.5904",
language = "English (US)",
volume = "86",
pages = "5904--5911",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion

AU - Anderson, S. M.

AU - Wideman, L.

AU - Patrie, J. T.

AU - Weltman, A.

AU - Bowers, C. Y.

AU - Veldhuis, Johannes D

PY - 2001

Y1 - 2001

N2 - Female gender confers resistance to GH autonegative feedback in the adult rat, thereby suggesting gonadal or estrogenic modulation of autoregulation of the somatotropic axis. Here we test the clinical hypothesis that short-term E2 replacement in ovariprival women reduces GH's repression of spontaneous, GHRH-, and GH-releasing peptide (GHRP)-stimulated GH secretion. To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17β-E2 orally twice daily for 6-23 d]. The GH autofeedback paradigm consisted of a 6-min pulsed iv infusion of recombinant human GH (10 μg/kg square-wave injection) or saline (control) followed by iv bolus GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or saline 2 h later. Blood was sampled every 10 min and serum GH concentrations were measured by chemiluminescence. Poststimulus GH release was quantitated by multiparameter deconvolution analysis using published biexponential kinetics and by the incremental peak serum GH concentration response (maximal poststimulus value minus prepeak nadir). Outcomes were analyzed on the logarithmic scale by mixed-effects ANOVA at a multiplecomparison type I error rate of 0.05. E2 supplementation increased the (mean ± SEM) serum E2 concentration from 43 ± 1.8 (control) to 121 ± 4 pg/ml (E2) (158 ± 6.6 to 440 ± 15 pmol/ liter; P < 0.001), lowered the 0800 h (preinfusion) serum IGF-I concentration from 127 ± 7.7 to 73 ± 3.6 μg/liter (P < 0.01), and amplified spontaneous pulsatile GH production from 7.5 ± 1.1 to 13 ± 2.3 μg/liter per 6 h (P = 0.020). In the absence of exogenously imposed GH autofeedback, E2 replacement enhanced the stimulatory effect of GHRP-2 on incremental peak GH release by 1.58-fold [95% confidence interval, 1.2- to 2.1fold] (P = 0.0034) but did not alter the action of GHRH (0.83fold [0.62- to 1.1-fold]). In the E2-deficient state, bolus GH infusion significantly inhibited subsequent spontaneous, GHRH-, and GHRP-induced incremental peak GH responses by, respectively, 33% (1-55%; P = 0.044 vs. saline), 79% (68-86%; P < 0.0001), and 54% (32-69%; P = 0.0002). E2 repletion failed to influence GH autofeedback on either spontaneous or GHRH-stimulated incremental peak GH output. In contrast, E2 replenishment augmented the GHRP-2-stimulated incremental peak GH response in the face of GH autoinhibition by 1.7-fold (1.2- to 2.5-fold; P = 0.009). Mechanistically, the latter effect of E2 mirrored its enhancement of GH-repressed/GHRP2-stimulated GH secretory pulse mass, which rose by 1.5-fold (0.95- to 2.5-fold over placebo; P = 0.078). In summary, the present clinical investigation documents the ability of short-term oral E2 supplementation in postmenopausal women to selectively rescue GHRP-2 (but not spontaneous or GHRH)stimulated GH secretion from autonegative feedback. The secretagogue specificity of E's relief of GH autoinhibition suggests that this sex steroid may enhance activity of the hypothalamopituitary GHRP-receptor/effector pathway.

AB - Female gender confers resistance to GH autonegative feedback in the adult rat, thereby suggesting gonadal or estrogenic modulation of autoregulation of the somatotropic axis. Here we test the clinical hypothesis that short-term E2 replacement in ovariprival women reduces GH's repression of spontaneous, GHRH-, and GH-releasing peptide (GHRP)-stimulated GH secretion. To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17β-E2 orally twice daily for 6-23 d]. The GH autofeedback paradigm consisted of a 6-min pulsed iv infusion of recombinant human GH (10 μg/kg square-wave injection) or saline (control) followed by iv bolus GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or saline 2 h later. Blood was sampled every 10 min and serum GH concentrations were measured by chemiluminescence. Poststimulus GH release was quantitated by multiparameter deconvolution analysis using published biexponential kinetics and by the incremental peak serum GH concentration response (maximal poststimulus value minus prepeak nadir). Outcomes were analyzed on the logarithmic scale by mixed-effects ANOVA at a multiplecomparison type I error rate of 0.05. E2 supplementation increased the (mean ± SEM) serum E2 concentration from 43 ± 1.8 (control) to 121 ± 4 pg/ml (E2) (158 ± 6.6 to 440 ± 15 pmol/ liter; P < 0.001), lowered the 0800 h (preinfusion) serum IGF-I concentration from 127 ± 7.7 to 73 ± 3.6 μg/liter (P < 0.01), and amplified spontaneous pulsatile GH production from 7.5 ± 1.1 to 13 ± 2.3 μg/liter per 6 h (P = 0.020). In the absence of exogenously imposed GH autofeedback, E2 replacement enhanced the stimulatory effect of GHRP-2 on incremental peak GH release by 1.58-fold [95% confidence interval, 1.2- to 2.1fold] (P = 0.0034) but did not alter the action of GHRH (0.83fold [0.62- to 1.1-fold]). In the E2-deficient state, bolus GH infusion significantly inhibited subsequent spontaneous, GHRH-, and GHRP-induced incremental peak GH responses by, respectively, 33% (1-55%; P = 0.044 vs. saline), 79% (68-86%; P < 0.0001), and 54% (32-69%; P = 0.0002). E2 repletion failed to influence GH autofeedback on either spontaneous or GHRH-stimulated incremental peak GH output. In contrast, E2 replenishment augmented the GHRP-2-stimulated incremental peak GH response in the face of GH autoinhibition by 1.7-fold (1.2- to 2.5-fold; P = 0.009). Mechanistically, the latter effect of E2 mirrored its enhancement of GH-repressed/GHRP2-stimulated GH secretory pulse mass, which rose by 1.5-fold (0.95- to 2.5-fold over placebo; P = 0.078). In summary, the present clinical investigation documents the ability of short-term oral E2 supplementation in postmenopausal women to selectively rescue GHRP-2 (but not spontaneous or GHRH)stimulated GH secretion from autonegative feedback. The secretagogue specificity of E's relief of GH autoinhibition suggests that this sex steroid may enhance activity of the hypothalamopituitary GHRP-receptor/effector pathway.

UR - http://www.scopus.com/inward/record.url?scp=0035215942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035215942&partnerID=8YFLogxK

U2 - 10.1210/jc.86.12.5904

DO - 10.1210/jc.86.12.5904

M3 - Article

C2 - 11739462

AN - SCOPUS:0035215942

VL - 86

SP - 5904

EP - 5911

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -